STAR Market's Innovative Drug Companies "Firing on All Cylinders"

China Fund News Delivery – The 2025 World Conference on Lung Cancer (WCLC) was recently held in Barcelona, Spain. Key studies from STAR Market innovative drug companies BeiGene, Biokin, and Dizal were selected for oral presentations at this year's conference, highlighting the international recognition of Chinese innovative drugs. Two studies on iza-bren (EGFR×HER3 bispecific ADC) developed independently by Biokin for the treatment of EGFR-mutant lung cancer were selected for the WCLC official press program and delivered as oral presentations, with one study achieving an objective response rate (ORR) of 100%, drawing widespread attention in the industry. Currently, the STAR Market gathers over 30 innovative drug companies. This year alone, it has facilitated the approval of 7 globally "first-in-class" Category 1 new drugs, bringing the cumulative total to 33, accounting for 14% of domestically developed Category 1 new drugs during the same period. Since the beginning of 2025, STAR Market innovative drug companies have completed 14 licensing transactions for pipeline assets, with a potential total transaction value exceeding USD 12 billion. (Reporter: Ying Mo)